HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


L’Oreal Buys Back Shares From Nestle, Sells Galderma Stake

This article was originally published in The Rose Sheet

Executive Summary

To finance a deal to purchase more than €6 billion of its own shares back from Nestle SA, L’Oreal SA has given up its half of skin-care company Galderma.

You may also be interested in...

M&A Heats Up As Major Players Eye New Markets, Categories

The Estee Lauder Companies has its eyes peeled for potential acquisitions on the order of its MAC buy in the 1990s, making it one of a number of cosmetics firms with cash in hand and a view toward expansion. Kline & Company notes that the M&A market is heating up as the global economy improves and companies look to position themselves better in emerging markets and new product categories.

Nestle Will Sweeten Its Skin-Care Offering With Valeant Derm Brands

Swiss food and beverage company Nestle SA is growing its stake in skin care, particularly in North America, with its pending $1.4 billion acquisition of five aesthetic dermatology brands from Valeant Pharmaceuticals International Inc., which would be folded into the firm’s Nestle Skin Care Health division. Subject to regulatory approval, the deal demonstrates the firm’s new commitment to health and wellness, says analyst.

Prospect Of L’Oreal Share Buyback Excites Investors

Sanofi SA has the cash to buy back about $12 billion worth of shares in its company that are currently owned by French beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says during Sept. 13 conference. L’Oreal CEO Agon suggested in recent earnings call that his firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts